Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

My Thoughts and Analysis On Phathom's Prospects For Success Investment Overview Analysing Phathom's Steady Share Price Declines Since Post-IPO Peak Looking Ahead - Can Phathom Stage A Recovery As A Commercial Entity & Secure Additional Approval Next Month? I last covered Phathom Pharmaceuticals (NASDAQ:PHAT) for Seeking Alpha around three and a half years ago, in January 2021, when the biotech's stock traded ~$39 per share, more than double its October 2019 IPO price of $19 per share (the IPO raised >$200m) ...